Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as
irinotecan, fluorouracil, and capecitabine, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Giving
bevacizumab together with combination chemotherapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well bevacizumab given together with combination
chemotherapy works in treating patients with metastatic colorectal cancer.